RNS - Great News10 Jan 2019 16:09
Angle PLC BREAKTHROUGH CANCER RESEARCH USING PARSORTIX
Source: UK Regulatory (RNS & others)
TIDMAGL
RNS Number : 7590M
Angle PLC
10 January 2019
For immediate release 10 January 2019
ANGLE plc ("the Company")
BREAKTHROUGH RESEARCH USING THE PARSORTIX SYSTEM HIGHLIGHTS POTENTIAL TO TRANSFORM CANCER TREATMENT BY SUPPRESSING CANCER METASTASIS
Research using Parsortix to isolate CTC clusters from blood identifies drugs which dissociate highly metastatic CTC clusters resulting in a near total elimination of metastasis in animal models
Opportunity for Parsortix liquid biopsy to be routinely used to identify patients who may benefit from the new approach to suppress cancer metastasis
University of Basel planning to commence clinical trial in breast cancer in 2019
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce that its Parsortix(TM) system has been utilised in ground-breaking new cancer research, which may provide a novel way to treat cancer through the suppression of cancer metastasis.
The research, led by Professor Nicola Aceto at the Cancer Metastasis Laboratory, University of Basel (Basel, Switzerland) has been published today as a peer-reviewed publication in the prestigious journal Cell.
The research demonstrated the ability to harvest intact metastatic circulating tumor cell clusters (CTC clusters, a group of cancer and other cells tethered together as a single mass) using Parsortix and highlights the potential to treat cancer patients identified with Parsortix to have CTC clusters with repurposed FDA approved medications, which have been shown in mouse models to break up these CTC clusters and suppress metastasis. Basel's research indicated that treated animals showed 80x less metastasis compared with untreated animals, with the metastatic spread of cancer virtually eliminated in the treated animals.
The development of metastasis, the spread of cancer to distant sites primarily via the blood, is responsible for more than 90% of all cancer-related deaths. Previous work has shown that CTC clusters in the blood are highly metastatic causing greatly increased spread of the disease. If metastasis could be suppressed by disrupting CTC clusters then patient outcomes could be dramatically improved.
There are a variety of technical challenges to capturing intact CTC clusters from patient blood, which has historically led to problems with other CTC systems and an inability to effectively research CTC clusters. In controlled tests with spiked samples, Basel demonstrated that the Parsortix system used with a specialised protocol performed exceptionally well to overcome these technical challenges and was able to successfully isolate >99% of CTC clusters from a simple blood test.
Using the Parsortix system, Basel was able to investigate CTC clusters both from patient blood and from animal models. The analysis of the CTC clusters led to Basel discovering
Sign In
Follow the stocks
